CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW
A comparison of the possibilities of using various neurotropic radiopharmaceuticals for scintigraphic evaluation of cerebral perfusion. In the whole range of radiopharmaceuticals used to diagnose cerebral blood flow disorders, there are Ceretec (99mTc-hexamethylpropyleneamine) and Neurolite (N,N-1,2...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Luchevaya Diagnostika, LLC
2017-03-01
|
| Series: | Вестник рентгенологии и радиологии |
| Subjects: | |
| Online Access: | https://www.russianradiology.ru/jour/article/view/196 |
| _version_ | 1797341671389659136 |
|---|---|
| author | N. Yu. N.Yu. Efimova N. G. Krivonogov Yu. B. Lishmanov I. Yu. Efimova |
| author_facet | N. Yu. N.Yu. Efimova N. G. Krivonogov Yu. B. Lishmanov I. Yu. Efimova |
| author_sort | N. Yu. N.Yu. Efimova |
| collection | DOAJ |
| description | A comparison of the possibilities of using various neurotropic radiopharmaceuticals for scintigraphic evaluation of cerebral perfusion. In the whole range of radiopharmaceuticals used to diagnose cerebral blood flow disorders, there are Ceretec (99mTc-hexamethylpropyleneamine) and Neurolite (N,N-1,2-ethylenediylbis-L-cysteine-diethyl ether), which are the most optimal agents. Due to their high cost and related radiation exposure, the radiopharmaceuticals 123І-IMP (123I-isopropyl-iodoamphetamine) and 201Tl-DDC (diethyldithiocarbamate) labeled with thallium-201 virtually minimize the possibilities of being used in daily clinical practice. Fixation of 99mTc-DDC in the brain proves to be short-term, which is insufficient for tomoscintigraphy studies. Literature has been sought in the Scopus, Web of Scince, Pubmed, EMBASE, and Russian Science Citation Index databases. |
| first_indexed | 2024-03-08T10:22:23Z |
| format | Article |
| id | doaj.art-1eb15a47c8bb44e78972cfd1c9da03a0 |
| institution | Directory Open Access Journal |
| issn | 0042-4676 2619-0478 |
| language | English |
| last_indexed | 2024-03-08T10:22:23Z |
| publishDate | 2017-03-01 |
| publisher | Luchevaya Diagnostika, LLC |
| record_format | Article |
| series | Вестник рентгенологии и радиологии |
| spelling | doaj.art-1eb15a47c8bb44e78972cfd1c9da03a02024-01-27T18:38:34ZengLuchevaya Diagnostika, LLCВестник рентгенологии и радиологии0042-46762619-04782017-03-01981444910.20862/0042-4676-2017-98-1-44-49162CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOWN. Yu. N.Yu. Efimova0N. G. Krivonogov1Yu. B. Lishmanov2I. Yu. Efimova3Сardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian Federation; Tomsk Polytechnic University, prospect Lenina, 30, Tomsk, 634050, Russian FederationСardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian FederationСardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian Federation; Tomsk Polytechnic University, prospect Lenina, 30, Tomsk, 634050, Russian FederationСardiology Research Institute, ul. Kievskaya, 111a, Tomsk, 634012, Russian FederationA comparison of the possibilities of using various neurotropic radiopharmaceuticals for scintigraphic evaluation of cerebral perfusion. In the whole range of radiopharmaceuticals used to diagnose cerebral blood flow disorders, there are Ceretec (99mTc-hexamethylpropyleneamine) and Neurolite (N,N-1,2-ethylenediylbis-L-cysteine-diethyl ether), which are the most optimal agents. Due to their high cost and related radiation exposure, the radiopharmaceuticals 123І-IMP (123I-isopropyl-iodoamphetamine) and 201Tl-DDC (diethyldithiocarbamate) labeled with thallium-201 virtually minimize the possibilities of being used in daily clinical practice. Fixation of 99mTc-DDC in the brain proves to be short-term, which is insufficient for tomoscintigraphy studies. Literature has been sought in the Scopus, Web of Scince, Pubmed, EMBASE, and Russian Science Citation Index databases.https://www.russianradiology.ru/jour/article/view/196review<sub>99m</sub>tc-hexamethylpropyleneaminen,n-1,2-ethylenediylbis-l-cysteine-diethyl ethercerebral perfusion |
| spellingShingle | N. Yu. N.Yu. Efimova N. G. Krivonogov Yu. B. Lishmanov I. Yu. Efimova CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW Вестник рентгенологии и радиологии review <sub>99m</sub>tc-hexamethylpropyleneamine n,n-1,2-ethylenediylbis-l-cysteine-diethyl ether cerebral perfusion |
| title | CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW |
| title_full | CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW |
| title_fullStr | CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW |
| title_full_unstemmed | CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW |
| title_short | CURRENT POSSIBILITIES OF USING RADIOPHARMACEUTICALS TO EVALUATE CEREBRAL BLOOD FLOW |
| title_sort | current possibilities of using radiopharmaceuticals to evaluate cerebral blood flow |
| topic | review <sub>99m</sub>tc-hexamethylpropyleneamine n,n-1,2-ethylenediylbis-l-cysteine-diethyl ether cerebral perfusion |
| url | https://www.russianradiology.ru/jour/article/view/196 |
| work_keys_str_mv | AT nyunyuefimova currentpossibilitiesofusingradiopharmaceuticalstoevaluatecerebralbloodflow AT ngkrivonogov currentpossibilitiesofusingradiopharmaceuticalstoevaluatecerebralbloodflow AT yublishmanov currentpossibilitiesofusingradiopharmaceuticalstoevaluatecerebralbloodflow AT iyuefimova currentpossibilitiesofusingradiopharmaceuticalstoevaluatecerebralbloodflow |